PMID- 33209051
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1178-7066 (Print)
IS  - 1178-7066 (Electronic)
IS  - 1178-7066 (Linking)
VI  - 13
DP  - 2020
TI  - Association Between Cannabinoid Receptor-1 Gene Polymorphism and the Risk of 
      Diabetic Nephropathy Among Patients with Type 2 Diabetes Mellitus.
PG  - 591-599
LID - 10.2147/PGPM.S278897 [doi]
AB  - BACKGROUND: The cannabinoid receptor 1 (CNR1) gene polymorphism is reportedly 
      associated with components of metabolic syndrome and coronary artery diseases in 
      patients with type 2 diabetes mellitus (T2DM). We investigated whether the common 
      variant rs10493353 polymorphism is associated with diabetic nephropathy (DN) in 
      T2DM patients. PATIENTS AND METHODS: T2DM patients with DN were enrolled as a 
      case group, and patients with only T2DM as a control group. Demographic data and 
      biochemical parameters were collected. The polymerase chain reaction-based 
      restriction fragment length polymorphism technique was used for genotyping. The 
      odds ratio and 90% confidence interval were calculated to assess the association 
      between genotypes and the risk of DN. RESULTS: In total, 320 T2DM patients and 
      320 DN patients were enrolled. Compared with T2DM patients, the DN patients have 
      a significantly larger body mass index (BMI), longer duration of disease, and 
      higher proportions of smokers, drinkers, and hypertension. The risk of DN was 
      significantly decreased by genotypes AA (OR=0.39, 95% CI=0.23-0.67) and GA 
      (OR=0.53, 95% CI=0.37-0.75) vs GG (codominant model), GA/AA vs GG (OR=0.49, 95% 
      CI=0.35-0.67; dominant model), AA vs GG/GA (OR=0.47, 95% CI=0.28-0.80; recessive 
      model), and the A allele (OR=0.52, 95% CI=0.40-0.68; allele model). Multiple 
      logistic regressions still show significant levels. Negative interactions were 
      found between gene and clinical parameters, including drinking, smoking, BMI, and 
      hypertension. CONCLUSION: The A allele of CNR1 gene rs10493353 may be a 
      protective factor for DN in T2DM patients. The risk factors of DN can affect the 
      protective role of A allele in the progression of DN.
CI  - (c) 2020 Zhang et al.
FAU - Zhang, Xuelian
AU  - Zhang X
AD  - Department of Endocrinology, China-Japan Friendship Hospital, Beijing 100029, 
      People's Republic of China.
FAU - Zhu, Haiqing
AU  - Zhu H
AD  - Department of Endocrinology, Emergency General Hospital, Beijing 100028, People's 
      Republic of China.
FAU - Xing, Xiaoyan
AU  - Xing X
AD  - Department of Endocrinology, China-Japan Friendship Hospital, Beijing 100029, 
      People's Republic of China.
FAU - Zhang, Chunyu
AU  - Zhang C
AD  - Department of Statistical Teaching and Research, China-Japan Friendship Hospital, 
      Beijing 100029, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20201112
PL  - New Zealand
TA  - Pharmgenomics Pers Med
JT  - Pharmacogenomics and personalized medicine
JID - 101514107
PMC - PMC7669503
OTO - NOTNLM
OT  - cannabinoid receptor 1
OT  - diabetes mellitus
OT  - diabetic nephropathy
OT  - gene polymorphism
COIS- The authors have no conflicts of interest to declare.
EDAT- 2020/11/20 06:00
MHDA- 2020/11/20 06:01
PMCR- 2020/11/12
CRDT- 2020/11/19 05:41
PHST- 2020/08/27 00:00 [received]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/11/19 05:41 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/11/20 06:01 [medline]
PHST- 2020/11/12 00:00 [pmc-release]
AID - 278897 [pii]
AID - 10.2147/PGPM.S278897 [doi]
PST - epublish
SO  - Pharmgenomics Pers Med. 2020 Nov 12;13:591-599. doi: 10.2147/PGPM.S278897. 
      eCollection 2020.